Estados Unidos · Plataformas y datos · MarketBeat

Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results

Publicado por MarketBeat · Estados Unidos hace 1 h

Satellos Bioscience (NASDAQ:MSLE) said it will use MRI-measured muscle fat fraction as the primary efficacy endpoint in its Phase II BASECAMP study of forazapadin for boys living…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results

También te puede interesar

Telus targets $900M annualized cash savings exiting 2028 while projecting $500M AI infrastructure revenue over 3 years

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?

Empery Digital director Tice Brown sells $1,193 in shares

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

Nasdaq drops into correction territory — here’s what typically happens next

Warren Buffett’s Berkshire Rose 5% in the Market’s Worst Week Since April 2025

Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results

Compartir

También te puede interesar

Telus targets $900M annualized cash savings exiting 2028 while projecting $500M AI infrastructure revenue over 3 years

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?

Empery Digital director Tice Brown sells $1,193 in shares

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

Nasdaq drops into correction territory — here’s what typically happens next

Warren Buffett’s Berkshire Rose 5% in the Market’s Worst Week Since April 2025